English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

References 1. Munzone E, Curigliano G, Rocca A, Bonizzic G, Renne G, Goldhirsch A, Nolè F: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Research 2006, 8:R4 2. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol 2001, 15:1344–1359. 3. Holloway JN, Murthy S, El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-down-regulation in breast cancer cells: the role of nuclear factor-B. Mol Endocrinol 2004, 18:1396–1410. Correction Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy Elisabetta Munzone1 Giuseppe Curigliano1, Andrea Rocca1, Giuseppina Bonizzi2, Giuseppe Renne3, Aron Goldhirsch1and Franco Nolè1

breast cancer research

Erratum to: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy